Inibição seletiva da ciclo-oxigenase-2: Riscos e benefícios

Revista Brasileira de Reumatologia

Volumn 52, Issue 5, 2012, Pages 774-782

  Mendes, Reila Tainá ^a   Stanczyk, Cassiano Pereira ^a   Sordi, Regina ^b   Otuki, Michel Fleith ^a   dos Santos, Fábio André ^a   Fernandes, Daniel ^a  

^a STATE UNIVERSITY OF PONTA GROSSA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872412907     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0482-50042012000500011     Document Type: Review

References (68)

1. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003; 290(18):2443-54.
2. a ed. Rio de Janeiro, 2008.
3. Pedroso ERP, Gomes R. Black Book - Clínica Médica. Belo Horizonte: 2007.
4. Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-infl ammatory drugs. Nat Rev Drug Discov 2006; 5(1):75-86.
5. Wilcox CM, Alexander LN, Cotsonis GA, Clark WS. Nonsteroidal Antiinfl ammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci 1997; 42(5):990-7.
6. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinfl ammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90(24):11693-7.
7. Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 2006; 1(4):420-39.
8. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 2009; 49:123-50.
9. Grosser T, Yusuff S, Cheskis E, Pack MA, FitzGerald GA. Developmental expression of functional cyclooxygenases in zebrafi sh. Proc Natl Acad Sci USA 2002; 99(12):8418-23.
10. Williams TJ, Peck MJ. Role of prostaglandin-mediated vasodilatation in infl ammation. Nature 1977; 270(5637):530-2.
11. Ferreira SH. Prostaglandins, aspirin-like drugs and analgesia. Nat New Biol 1972; 240(102):200-3.
12. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001; 108(1):25-30.
13. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetaminophenol). Nature 1972; 240(5381):410-1.
14. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99(21):13926-31.
15. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116(1):4-15.
16. Brzozowski T, Konturek PC, Konturek SJ, Brzozowska I, Pawlik T. Role of prostaglandins in gastroprotection and gastric adaptation. J Physiol Pharmacol 2005; 56(Suppl. 5):33-55.
17. Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993; 119(4):257-62.
18. Seibert K, Masferrer J, Zhang Y, Gregory S, Olson G, Hauser S et al. Mediation of infl ammation by cyclooxygenase-2. Agents Actions Suppl 1995; 46:41-50.
19. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of ciclooxygenase-2. N Engl J Med 2001; 345(6):433-42.
20. Hawkey CJ. COX-2 chronology. Gut 2005; 54(11):1509-14.
21. Grosser T, Yu Y, Fitzgerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med 2010; 61:17-33.
22. Patrono C, Baigert C. Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. Mol Interv 2009; 9(1):31-9.
23. Amer M, Bead VR, Bathon J, Blumenthal RS, Edwards DN. Use of nonsteroidal anti-infl amatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol Rev 2010; 18(4):204-12.
24. Hinz B, Renner B, Brune K. Drug insight: cyclo-oxygenase-2 inhibitors - a critical appraisal. Nat Clin Pract Rheumatol 2007; 3(10):552-60.
25. Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insights into COX-2 biology and inhibition. Brain Res Rev 2005; 48(2):352-9.
26. Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An update meta-analysis. J Hipertens 2009; 27(12):2332-41.
27. Huber MA, Terezhalmy GT. The use of COX-2 inhibitors for acute dental pain: A second look. J Am Dent Assoc 2006; 137(4):480-7.
28. Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 2008; 64(3):233-52.
29. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004; 351(17):1709-11.
30. Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet. 2004; 364(9450):1995-6.
31. Vaithianathan R, Hockey PM, Moore TJ, Bates DW. Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey. Drug Saf 2009; 32(4):335-3.
32. Topol EJ. Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351(17):1707-9.
33. Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME et al. Specifi c inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999; 13(6):761-7.
34. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282(20):1929-33.
35. Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002; 14(10):1101-11.
36. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC et al. Anti-infl ammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282(20):1921-8.
37. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L et al. Effects of specifi c inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289(2):735-41.
38. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96(1):272-7.
39. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis R et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343(21):1520-8.
40. Franco GCN, Moretti D, Cavalcante PFC, Lopes LC. Uma análise crítica sobre a viabilidade do uso dos inibidores seletivos de COX-2 em odontologia. Revista de Odontologia da Universidade Cidade de São Paulo 2006; 18(1):75-81.
41. Hsiang KW, Chen TS, Lin HY, Luo JC, Lu CL, Lin HC et al. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: a prospective, observational, cohort study in Taiwan. Clin Ther 2010; 32(7):1294-303.
42. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release. Arch Intern Med 2005; 165(2):171-7.
43. o 79, de 4 de novembro de 2008.
44. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002; 296(5567):539-41.
45. Smyth EM, FitzGerald GA. Human prostacyclin receptor. Vitam Horm 2002; 65:149-65.
46. Nyman I, Larsson H, Wallentin L. Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. The Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Lancet 1992; 340(8818):497-501.
47. Bishop-Bailey D, Mitchell JA, Warner TD. COX-2 in cardiovascular disease. Arterioscler Thromb Vasc Biol 2006; 26(5):956-8.
48. Grosser T. The pharmacology of selective inhibition of COX-2. Thromb Haemost 2006; 96(4):393-400.
49. Fries S, Grosser T, Price TS, Lawson JA, Kapoor S, DeMarco S et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006; 130(1):55-64.
50. Schwartz Z, Denison TA, Bannister SR, Cochran DL, Liu YH, Lohmann CH et al. Osteoblast response to fl uid induced shear depends on substrate microarchitecture and varies with time. J Biomed Mater Res. 2007; 83(1):20-32.
51. Inoue H, Taba Y, Miwa Y, Yokota C, Miyagi M, Sasaguri T. Transcriptional and posttranscriptional regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22(9):1415-20.
52. Topper JN, Cai J, Falb D, Gimbrone MA. Identifi cation of vascular endothelial genes differentially responsive to fl uid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 1996; 93(19):10417-22.
53. Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999; 19(3):646-55.
54. Schönbeck U, Sukhowa GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155(4):1281-91.
55. Stemme V, Swedenborg J, Claesson H, Hansson GK. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg 2000; 20(2):146-52.
56. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310(17):1065-8.
57. Roy L, Knapp HR, Robertson RM, FitzGerald GA. Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man. Circulation 1985; 71(3):434-40.
58. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102(8):840-5.
59. Patrono C, Patrignani P, García Rodríguez LA. Cyclooxygenaseselective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001; 108(1):7-13.
60. Trelle S, Reichenbach S, Eandel S, Hildebrand P, Tschannen B, Villiger PM et al. Cardiovascular safety of non-steroidal antiinfl ammatory drugs: network meta-analysis. BMJ 2011; 342:c7086.
61. US Food and Drug Administration. Alert for healthcare professionals: non-selective non-steroidal anti-infl ammatory drugs (NASIDs). Available from: http://www.fda.gov /cder/drug/InfoSheets/HCP/ NS_NSAIDsHCP.htm.
62. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296(13):1633-44.
63. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet 2006; 368(9549):1771-81.
64. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165(5):490-6.
65. Hao CM, Breyer MD. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 2008; 70:357-77.
66. Schwartz JI, Dallob AL, Larson PJ, Laterza OF, Miller J, Royalty KM et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol 2008; 48(6):745-54.
67. Sheinberg M. Anti-infl amatórios e anti-infl amatórios - Opinião. Folha de São Paulo 2009.
68. Warner TD, Mitchell JA. Cicloxygenases: new forms, new inhibitors, and lessons froms the clinic. The FASEB Journal 2004; 18(7):790-804.